| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vascular Biology |
From the Department of Regenerative Medicine (S.M., A.K., M.H., S.N., T.A.), Institute of Biomedical Research and Innovation/Stem Cell Translational Research, RIKEN Center for Developmental Biology, Kobe, Japan; and the Department of Physiology (T.A.), Tokai University School of Medicine, Japan.
Correspondence to Dr Takayuki Asahara, Department of Regenerative Medicine, Institute of Biomedical Research and Innovation /Stem Cell Translational Research, RIKEN Center for Developmental Biology, Japan 2-2 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan. E-mail asa777{at}aol.com
Objective Previous studies from our laboratory have shown therapeutic potential of ex vivo expanded endothelial progenitor cells (EPCs) for myocardial ischemia. Our purpose was to investigate the mechanisms regulating EPC contribution to myocardial regeneration.
Methods and Results To evaluate niche-dependent expression profiles of EPCs in vitro, we performed coculture using cultured EPCs derived from human peripheral blood and rat cardiac myoblast cell line (H9C2). Reverse-transcription polymerase chain reaction (PCR) disclosed the expression of human-specific cardiac markers as well as human-specific smooth muscle markers. Cytoimmunochemistry presented several cocultured cells stained with human specific cardiac antibody. To prove this translineage differentiation in vivo, human cultured EPCs were injected into nude rat myocardial infarction model. Reverse-transcription PCR as well as immunohistochemistry of rat myocardial samples demonstrated the expression of human specific cardiac, vascular smooth muscle, and endothelial markers. We observed the distribution of colors (Qtracker; Quantum Dot Corp) in coculture to detect the fused cells, and the frequency of cell fusion was <1%.
Conclusions EPCs can contribute to not only vasculogenesis but also myogenesis in the ischemic myocardium in vivo. Transdifferentiation, not cell fusion, is dominant for EPCs commitment to myocardial lineage cells. Ex vivo expanded EPCs transplantation might have enhanced therapeutic potential for myocardial regeneration.
Ex vivo expanded EPC transplantation has shown therapeutic potential for myocardial ischemia. We observed the expression of human-specific cardiac, vascular smooth muscle, and endothelial markers in niche-dependent expression profiles of EPCs via mainly transdifferentiation. EPCs could contribute to not only vasculogenesis but also myogenesis in the ischemic myocardium.
Key Words: cardiovascular diseases endothelial myocardium regeneration stem cells vasculogenesis
This article has been cited by other articles:
![]() |
S. Rupp, M. Koyanagi, M. Iwasaki, J. Bauer, S. von Gerlach, D. Schranz, A. M. Zeiher, and S. Dimmeler Characterization of long-term endogenous cardiac repair in children after heart transplantation Eur. Heart J., May 28, 2008; (2008) ehn223v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Urayama, C. Guilini, G. Turkeri, S. Takir, H. Kurose, N. Messaddeq, A. Dierich, and C. G. Nebigil Prokineticin Receptor-1 Induces Neovascularization and Epicardial-Derived Progenitor Cell Differentiation Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 841 - 849. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Muller, A. Kazakov, A. Semenov, M. Bohm, and U. Laufs Pressure-induced cardiac overload induces upregulation of endothelial and myocardial progenitor cells Cardiovasc Res, January 1, 2008; 77(1): 151 - 159. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Koyanagi, P. Bushoven, M. Iwasaki, C. Urbich, A. M. Zeiher, and S. Dimmeler Notch Signaling Contributes to the Expression of Cardiac Markers in Human Circulating Progenitor Cells Circ. Res., November 26, 2007; 101(11): 1139 - 1145. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bearzi, M. Rota, T. Hosoda, J. Tillmanns, A. Nascimbene, A. De Angelis, S. Yasuzawa-Amano, I. Trofimova, R. W. Siggins, N. LeCapitaine, et al. Human cardiac stem cells PNAS, August 28, 2007; 104(35): 14068 - 14073. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Prunier, O. Pfister, L. Hadri, L. Liang, F. del Monte, R. Liao, and R. J. Hajjar Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H522 - H529. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |